Cancer incidence in the United Kingdom: Projections to the year 2030

Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Barts & The London School of Medicine & Dentistry, Queen Mary University of London, Charterhouse Square, London, UK.
British Journal of Cancer (Impact Factor: 4.82). 11/2011; 105(11):1795-803. DOI: 10.1038/bjc.2011.430
Source: PubMed

ABSTRACT Projections of cancer incidence are important for planning health services and to provide a baseline for assessing the impact of public health interventions.
Rates estimated from smooth function age-period-cohort modelling of cancer incidence data from Great Britain 1975 to 2007 are extrapolated to 2030 and applied to UK population projections. Prostate and breast cancer projections take into account the effect of screening.
Overall rates of cancer are projected to be stable over the next 20 years, but this masks individual changes. In both sexes, age-standardised rates of cancers of the stomach, larynx, bladder and leukaemia are projected to fall by ≥1% per year, whereas cancers of the lip, mouth and pharynx (ICD-10 C00-C14) and melanoma are projected to increase by ≥1% per year. The growing and aging populations will have a substantial impact: numbers of cancers in men and women are projected to increase by 55% (from 149,169 to 231,026) and 35% (from 148,716 to 200,929), respectively, between 2007 and 2030. The model used yields similar results to those of Nordpred, but is more flexible.
Without new initiatives for smoking and obesity reduction, the number of cancers in the United Kingdom will increase substantially reflecting the growing and aging populations.

Download full-text


Available from: Amar S Ahmad, Oct 06, 2014
1 Follower
  • Source
    • ") showed a higher incidence for all cancers (excluding non-melanoma skin cancer) in males and females aged from 65 to 74 and 75+years old than in individuals from 10 to 14, 25–49, or 50–64 years old (Mistry et al. 2011). Reports are now emerging suggesting that increased frequency of MDSCs may play a role in the reduced immune surveillance of cancer. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Infections, cancer and autoimmune diseases occur more frequently in the elderly, and although many factors contribute to this, the age-related remodelling of the immune system, termed immunosenescence, plays a major role. Over the last two decades, studies have evaluated the effect of ageing on both the adaptive and innate arms of the immune system and demonstrated compromised function in several cells including lymphocytes (naïve, effector and memory), regulatory T and B cells, monocytes, neutrophils and NK cells. In addition, a well-documented feature of ageing is the increase in systemic inflammatory status (inflammageing), with raised serum levels of IL6, TNFα and CRP as well as reduced IL10. Recently, myeloid-derived suppressor cells have been the focus of many reports as these cells show immunosuppressive properties and are present in higher frequency during infections, cancer and autoimmunity. Importantly, there have been publications showing increased numbers of myeloid-derived suppressor cells in aged mice and humans. In this review, we discuss the current literature on myeloid-derived suppressor cells, their possible role in altered immune function in the elderly, and whether it may be possible to manipulate these cells to alleviate age-related immune dysfunction.
    Age 12/2014; 36(6):9729. DOI:10.1007/s11357-014-9729-x · 3.45 Impact Factor
  • Source
    • "To avoid overestimation of cases from the multiplicative model, as recommended by Olsen et al. (2008) and Mistry et al. (2011), a power of 5 function was used. The prediction model is written as: "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: Cervical cancer has been a leading female cancer in Thailand for decades, and has been second to breast cancer after 2007. The Ministry of Public Health (MoPH) has provided opportunistic screening with Pap smears for more than 30 years. In 2002, the MoPH and the National Health Security Office provided countrywide systematic screening of cervical cancer to all Thai women aged 35-60 years under universal health care coverage insurance scheme at 5-year intervals. Objectives: This study characterized the cervical cancer incidence trends in Songkhla in southern Thailand using joinpoint and age period cohort (APC) analysis to observe the effect of cervical cancer screening activities in the past decades, and to project cervical cancer rates in the province, to 2030. Materials and Methods: Invasive and in situ cervical cancer cases were extracted from the Songkhla Cancer Registry from 1990 through 2010. Age standardized incidence rates were estimated. Trends in incidences were evaluated by joinpoint and APC regression models. The Norpred package was modified for R and was used to project the future trends to 2030 using the power of 5 function and cut trend method. Results: Cervical cancer incidence in Songkhla peaked around 1998-2000 and then dropped by -4.7% per year. APC analysis demonstrated that in situ tumors caused an increase in incidence in early ages, younger cohorts, and in later years of diagnosis. Conclusions: Both joinpoint and APC analysis give the same conclusion in continuation of a declining trend of cervical cancer to 2030 but with different rates and the predicted goal of ASR below 10 or even 5 per 100,000 women by 2030 would be achieved. Thus, maintenance and improvement of the screening program should be continued. Other population based cancer registries in Thailand should analyze their data to confirm the success of cervical cancer screening policy of Thailand.
    Asian Pacific journal of cancer prevention: APJCP 12/2014; 15(22):10003-10008. DOI:10.7314/APJCP.2014.15.22.10003 · 2.51 Impact Factor
  • Source
    • "The efficiency of the dosages during the treatment is often measured as the interval of time from the start of therapy, until the end of treatment. Drug transport and metabolism enzymes also influence the toxic effects of both antineoplastic agents in target tumour cells and normal host tissues (Mistry et al., 2011). The most important challenge of cancer treatment is to retain/maintain the normal physiological states of the patient's body during the course of different treatment schedules. "
    [Show abstract] [Hide abstract]
    ABSTRACT: This paper presents an investigation into the development of an optimal chemotherapy drug(s) scheduling scheme to control the drug doses to be infused to the patient's body. The current standard of practice of treatment is based on empirical evidence gathered from preclinical and clinical trials carried out during the drug development process. In general, most chemotherapy drugs used in cancer treatments are toxic agents and usually have narrow therapeutic indices; dose levels at which these drugs significantly kill the cancerous cells are close to those levels at which harmful toxic side effects occur. Therefore, an effective chemotherapy treatment protocol requires advanced automation and treatment design tools for use in clinical practice and the challenges inherent to complex biomedical systems and clinical deployment of technology (Parker, 2009). An optimum but effective drug scheduling requires suitable balancing between the beneficial and toxic side effects. Conventional clinical methods very often fail to find right drug doses that balance between these two constraints due to their inherent conflicting nature. A Multi-objective Genetic Algorithm Optimization (MOGA) process is employed to find the desired drug concentration at tumour sites that trade-off between the conflicting objectives. A close-loop control method, namely Integral-Proportional-Derivative (I-PD) is designed to control the drug to be infused to the patient's body and MOGA is used to find suitable/acceptable drug concentration at tumour site and parameters of the controller. Cell cycle specific cancer tumour models have been used in this work to show the effects of drug(s) on different cell populations, drug concentrations and toxic side effects. Results show that the applied multi-objective optimization approach can produce a wide range of solutions that trade-off between cell killing and toxic side effects and satisfy associated goals of chemotherapy treatment. Depending on the physiological state of the patient and state of the cancer, the oncologist can pick the right solution suitable for the patient. The chemotherapy drug schedules obtained by the proposed treatment protocols appears to be continuous on the time (day) scale, i.e., specific amount of drugs to be administered to the patient on daily basis which can be termed as Metronomics in nature. The dose duration and the interval period between dose applications can be adjusted in the proposed scheme either by setting the sampling time of closed-loop I-PD controller to any value depending on the state of the patient and disease (model parameters) or by using genetic optimization process aiming to minimize/maximize treatment objectives and satisfying treatment constraints. Regarding the total duration of the treatment, clinical knowledge can be utilized giving emphasis on physiological state of the patient, state of the tumour and disease. Moreover, the total duration of the treatment can also be found/determined for specific values of model parameters describing physiological state of the patient, state of the tumour and disease through multi-objective optimization process. It is noted that the proposed scheme offered the best treatment performance as compared to the reported work available so far. Moreover, robustness analysis shows that the control scheme is highly stable and robust despite the model uncertainties; from small to wide range, and the percentage of proliferating cell reduction is almost same as it is found with optimum model parameters without having any uncertainty.
    Computers & Chemical Engineering 11/2013; 58:14–32. DOI:10.1016/j.compchemeng.2013.05.021 · 2.45 Impact Factor
Show more